Oral Cancer Screening: Early Detection, Risk Factors, and Biopsy Techniques

Category: Oral Medicine / Pathology | Keywords: oral cancer, screening, early detection, biopsy, potentially malignant disorders, leukoplakia, HPV, squamous cell carcinoma

1. Introduction

Oral squamous cell carcinoma (OSCC) accounts for over 90% of all oral malignancies and represents the sixth most common cancer worldwide, with approximately 377,000 new cases and 177,000 deaths annually (GLOBOCAN 2020). Despite advances in surgical and adjuvant therapies, the overall 5-year survival rate for oral cancer remains approximately 50–60%, a figure that has not improved substantially in four decades. This persistently poor prognosis is principally attributable to late-stage diagnosis: approximately 60% of OSCCs are diagnosed at Stage III or IV, when regional lymph node metastasis is already present. When detected at Stage I, the 5-year survival rate exceeds 80%, underscoring the critical importance of early detection through systematic oral cancer screening in the general dental practice.

Key statistic: The 5-year survival rate drops from >80% for localized Stage I disease to <40% for Stage IV disease with distant metastasis, highlighting the life-saving potential of opportunistic screening.

2. Epidemiology and Risk Factors

2.1 Global Burden and Temporal Trends

OSCC incidence demonstrates striking geographic variation, with the highest age-standardized rates observed in South and Southeast Asia (India, Sri Lanka, Bangladesh), where OSCC accounts for up to 30% of all cancers, driven largely by areca nut (betel quid) chewing and smokeless tobacco use. In Western countries, OSCC incidence has shown a concerning upward trend in younger (<45 years), non-smoking, non-drinking patients, a phenomenon attributed to high-risk human papillomavirus (HPV), particularly HPV-16.

2.2 Established Risk Factors

2.3 Emerging Risk Factors

• Chronic mechanical irritation: The role of chronic trauma from sharp teeth, ill-fitting dentures, or dental restorations as an independent risk factor remains controversial. While chronic irritation may promote tumor promotion in an already-initiated epithelium, the evidence does not support mechanical irritation as a primary initiator of OSCC.
• Oral microbiome dysbiosis: Emerging research implicates specific bacterial profiles—particularly increased abundance of Fusobacterium nucleatum, Porphyromonas gingivalis, and Candida albicans—in OSCC progression. The proposed mechanisms include chronic inflammation, production of carcinogenic metabolites (acetaldehyde from Candida), and immune evasion.
• Dietary factors: Diets low in fruits and vegetables (antioxidants, carotenoids, vitamins A, C, and E) confer a 2- to 3-fold increased risk. Conversely, high consumption of fresh fruits and vegetables is protective.

3. Oral Potentially Malignant Disorders (OPMDs)

3.1 Classification and Malignant Transformation Rates

OPMDs are clinical presentations that carry an increased risk of malignant transformation. The WHO Collaborating Centre for Oral Cancer classifies the following as OPMDs:

3.2 Clinical Features Meriting Urgent Referral

Any oral lesion or mucosal abnormality persisting for more than 2–3 weeks without identifiable cause warrants biopsy or specialist referral. High-risk clinical features include: non-homogeneous leukoplakia (speckled, verrucous, or nodular appearance); erythroplakia (any area, regardless of size); ulceration or induration within a white or red lesion; rapid growth; fixation to underlying tissues; and unexplained tooth mobility or non-healing extraction socket.

4. The Oral Cancer Screening Examination

4.1 Systematic Extraoral Examination

1. Facial inspection: Asymmetry, swelling, skin lesions (particularly of the lower lip and perioral skin)
2. Cervical lymph node palpation: Systematic examination of submental, submandibular, jugulodigastric, mid-cervical, posterior triangle, and supraclavicular nodes. Document size, consistency (firm, rubbery, hard), mobility, and tenderness. Nodes >1 cm, fixed to underlying structures, or hard in consistency are suspicious.
3. TMJ and parotid region: Palpation for masses or tenderness
4. Cranial nerve screening: Particularly CN V (sensory), CN VII (motor), CN IX/X (palatal elevation, gag reflex), CN XII (tongue deviation on protrusion)

4.2 Systematic Intraoral Examination

1. Labial mucosa and vestibular sulci: Retract lips, examine upper and lower sulci with mirror retraction
2. Buccal mucosa: Retract cheek with mirror; visualize from commissure to retromolar trigone bilaterally
3. Gingiva and alveolar ridges: Examine facial and lingual/palatal aspects of all gingival and edentulous ridge areas
4. Dorsal tongue: Grasp tongue tip with gauze and gently protrude; examine dorsum, lateral borders, and tip
5. Ventral tongue, floor of mouth, and lingual frenum: Elevate tongue to the palate; these are high-risk areas for OSCC and must be carefully visualized
6. Hard and soft palate: With patient's head tilted back, visualize the entire palate, including junction of hard and soft palate and uvula
7. Tonsillar pillars and posterior pharyngeal wall: Depress tongue and visualize as much of the oropharynx as possible (note: this is limited in the dental setting—refer for flexible laryngoscopy if oropharyngeal symptoms are present)

5. Adjunctive Screening Technologies

Evidence-based recommendation: Current systematic reviews conclude that no adjunctive screening device demonstrates sufficient specificity or positive predictive value to be recommended as a replacement for or routine adjunct to conventional oral examination. The 2013 Cochrane review found insufficient evidence to support population-based oral cancer screening with COE alone; however, opportunistic screening in high-risk populations within the dental setting is widely recommended by professional organizations (ADA, AAOMS, WHO), as it is non-invasive, cost-effective, and associated with downstaging of OSCC at diagnosis.

6. Biopsy Techniques

6.1 Indications for Biopsy

Biopsy is indicated for any oral lesion meeting the following criteria:

• Any red (erythroplakic) lesion, regardless of size or duration
• Any white lesion with high-risk features (non-homogeneous, ulcerated, indurated, symptomatic)
• Any mixed red-white lesion (erythroleukoplakia / speckled leukoplakia)
• Any ulcer or erosion persisting >2 weeks without identifiable etiology
• Any exophytic or submucosal mass with progressive growth
• Unexplained tooth mobility, non-healing extraction socket, or paresthesia
• Persistent hoarseness, dysphagia, or referred otalgia (requires ENT referral for direct laryngoscopy)

6.2 Biopsy Types and Technique

6.3 Biopsy Principles and Pitfalls

• Anesthesia: Use regional block rather than local infiltration to avoid tissue distortion and artifact; inject at least 1 cm from the lesion margin
• Specimen integrity: Avoid crushing the specimen with forceps (grasp at one corner or use a traction suture); avoid electrocautery through the specimen (produces thermal artifact that renders histopathologic interpretation difficult)
• Orientation: Place a marking suture at a designated margin (e.g., superior margin) and communicate orientation to the pathologist
• Hemostasis: Achieve hemostasis with pressure, silver nitrate, or judicious electrocautery (after specimen removal). Suture if needed.
• Documentation: Photograph the lesion before and after biopsy. Record exact location, size, clinical description, and clinical differential diagnosis on the pathology requisition.
• Avoiding pitfalls: Biopsy of a squamous cell carcinoma that samples only the superficial hyperkeratotic layer without the deeper invasive component leads to a false-negative "benign hyperkeratosis" diagnosis. Ensure adequate depth. Biopsy of a mucocele or ranula without including the associated minor salivary gland lobules leads to non-diagnostic results.

7. The Dental Team's Role in Prevention and Early Detection

7.1 Risk Factor Modification Counseling

General dental practitioners are uniquely positioned to provide repeated, long-term tobacco and alcohol cessation counseling. The "5 A's" model (Ask, Advise, Assess, Assist, Arrange follow-up) is effective in the dental setting. Even brief (3–5 minute) interventions increase tobacco cessation rates by 5–15% at 6 months. Similarly, HPV vaccination counseling for adolescents and young adults (age 9–26, with shared clinical decision-making for ages 27–45) represents a primary prevention opportunity. The 9-valent HPV vaccine (Gardasil 9) covers HPV-16 and HPV-18, which are responsible for approximately 70–80% of HPV-associated oropharyngeal cancers.

7.2 The Screening Encounter Protocol

Every patient presenting for a routine dental examination should receive an oral cancer screening as standard of care:

1. Update medical, social, and family history (tobacco, alcohol, areca nut use; HPV vaccination status; previous head and neck cancer)
2. Review of systems: inquire about persistent sore throat, hoarseness, dysphagia, odynophagia, otalgia, unexplained weight loss, or neck mass
3. Systematic extraoral and intraoral examination as described in Section 4
4. Documentation: Normal findings documented as "no clinically apparent oral mucosal abnormalities"; any lesion documented with size, location, color, morphology, duration, and photograph
5. Patient education: Explain findings; if OPMD is identified, educate the patient on the nature of the lesion, the rationale for biopsy or surveillance, and the importance of follow-up
6. Referral pathway: Establish relationships with local oral and maxillofacial surgeons, oral medicine specialists, or ENT surgeons to facilitate timely biopsy (ideally within 2 weeks of identification)

8. Future Directions

• Liquid biopsy: Circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in peripheral blood for screening, surveillance, and minimal residual disease detection
• Artificial intelligence and machine learning: Deep learning algorithms for automated detection and classification of oral lesions from clinical photographs; early studies show sensitivity of 85–95% and specificity of 80–90%
• Point-of-care molecular diagnostics: Chairside tests for HPV DNA, loss of heterozygosity (LOH), and other molecular markers to improve risk stratification of OPMDs
• Optical diagnostic technologies: Advanced OCT, confocal microscopy, and Raman spectroscopy for non-invasive, real-time, in vivo histopathologic assessment

9. Conclusion

Oral cancer remains a significant global health burden, with persistently poor survival rates attributable largely to late-stage diagnosis. The general dental practitioner occupies a critical position in the opportunistic screening pathway, as the majority of patients at risk for oral cancer visit their dentist more frequently than their physician. Systematic extraoral and intraoral examination, recognition of OPMDs, appropriate use of biopsy, and risk factor counseling are core competencies that every dentist must maintain. While adjunctive screening technologies continue to evolve, conventional oral examination remains the evidence-based standard of care. The imperative is clear: every dental examination must include a thorough oral cancer screening, as early detection directly translates into lives saved.

References

1. Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
2. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45(4-5):309-316.
3. Reibel J. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med. 2003;14(1):47-62.
4. Lingen MW, et al. Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity. J Am Dent Assoc. 2017;148(10):712-727.
5. Brocklehurst P, et al. Screening programmes for the early detection and prevention of oral cancer. Cochrane Database Syst Rev. 2013;(11):CD004150.
6. Epstein JB, et al. The limitations of the clinical oral examination in detecting dysplastic oral lesions and oral squamous cell carcinoma. J Am Dent Assoc. 2012;143(12):1332-1342.
7. Mehanna HM, et al. Head and neck cancer—Part 2: treatment and prognostic factors. BMJ. 2010;341:c4690.
8. Rethman MP, et al. Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. J Am Dent Assoc. 2010;141(5):509-520.
9. Poh CF, et al. Oral premalignant lesions: new insights and clinical implications. J Calif Dent Assoc. 2006;34(4):331-337.
10. Gillison ML, et al. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33(29):3235-3242.